Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06459635
Other study ID # 3513
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 9, 2023
Est. completion date December 2025

Study information

Verified date June 2024
Source Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Contact Ana Beatriz Gago Veiga
Phone +34 915202416
Email anabeatriz.gago@salud.madrid.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents.


Description:

Patients with episodic migraine will be recruited from the monographic headache clinics of the 7 centers participating in the study. These patients, for a maximum period of 2 months, must monitor their hemodynamic variables with a wearable device and record all the clinical characteristics of their migraine attacks. Subsequently, with these records, an individualized algorithm will be created for each patient that aims to predict the onset of the migraine attack.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 2025
Est. primary completion date September 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age between 15 years and 69 years. - Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3. - History of migraine of at least 1 year of evolution. - Normal neurological examination. - Have given your informed consent. - Be able to describe your clinical situation and the characteristics of your headache. - Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine). - User-level management capacity of "smartphone" type electronic devices. - Be able to complete two months of study follow-up. Exclusion Criteria: - Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication. - Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly. - Neurological focus in the examination. - Pregnancy or breastfeeding period. - Patients with known heart disease or bronchopathy, Sjögren's syndrome, diabetes mellitus, or hypo/hyperthyroidism. - Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult. - Anatomical problem that makes the use of the device impossible. - Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.

Study Design


Locations

Country Name City State
Spain Hospital Universitario de La Princesa Madrid

Sponsors (7)

Lead Sponsor Collaborator
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa Hospital Clínico Universitario de Valladolid, Hospital Clínico Universitario Lozano Blesa, Hospital Universitario Donostia, Hospital Universitario La Fe, Hospital Universitario Marqués de Valdecilla, Hospital Vall d'Hebron

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Gago-Veiga AB, Pagan J, Henares K, Heredia P, Gonzalez-Garcia N, De Orbe MI, Ayala JL, Sobrado M, Vivancos J. To what extent are patients with migraine able to predict attacks? J Pain Res. 2018 Sep 27;11:2083-2094. doi: 10.2147/JPR.S175602. eCollection 20 — View Citation

Pagan J, De Orbe MI, Gago A, Sobrado M, Risco-Martin JL, Mora JV, Moya JM, Ayala JL. Robust and Accurate Modeling Approaches for Migraine Per-Patient Prediction from Ambulatory Data. Sensors (Basel). 2015 Jun 30;15(7):15419-42. doi: 10.3390/s150715419. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Development of a prediction strategy for the onset of migraine Develop a prediction strategy for the onset of migraine attacks in patients with episodic migraine, based on hemodynamic and clinical variables of migraine attacks. From the beginning of treatment, which is the initial visit, to 2 months of follow-up
Secondary Posibility of predict the onset of pain in a migraine attack To analyze whether it is possible to predict the onset of pain in a migraine attack, through ambulatory and non-invasive monitoring of physiological variables. From the beginning of treatment, which is the initial visit, to 2 months of follow-up
Secondary Individualized prediction algorithm Implement an individualized prediction algorithm that allows real-time prediction of the symptomatic phase of the migraine attack. From the beginning of treatment, which is the initial visit, to 2 months of follow-up
Secondary Effectiveness of the prediction model Measure the effectiveness of the prediction model both at the individual level and in a large group of patients. From the beginning of treatment, which is the initial visit, to 2 months of follow-up
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A